BFRI

Biofrontera, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website biofrontera-us.com
Employees(FY) 81
ISIN US09077D2099

Performance

-7.69%

+27.33%

-23.55%

-2.15%

-64.68%

YTD

-71.22%

Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Advanced Technical Analysis

Technical Analysis of BFRI 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23, the Oscillators Score at 43, and the Technical Score at 33, indicating weakness in momentum and trend direction. The combined scores suggest a cautious outlook, as all indicators lean towards bearish territory, signaling potential challenges for upward...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BFRI

Stock Rank

Recent News & Updates

2024-12-02 22:00
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference(Yahoo Finance)
2024-11-21 20:10
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note(Globenewswire)
2024-11-13 04:15
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update(Globenewswire)
2024-10-31 23:55
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024(Accesswire)
2024-10-30 22:32
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)(Globenewswire)
2024-10-13 22:30
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz -Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)(Globenewswire)
2024-10-06 20:45
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment(Globenewswire)
2024-09-24 22:45
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference(Accesswire)
2024-09-24 22:45
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference(Yahoo Finance)
2024-08-14 04:30
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-08-08 22:00
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024(Accesswire)
2024-06-23 20:30
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED XL Lamp(Globenewswire)
2024-05-15 09:53
BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-15 04:45
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update(Accesswire)
2024-05-05 22:30
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024(Accesswire)
2024-05-02 20:50
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants(Accesswire)
2024-03-26 04:30
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals(Yahoo Finance)
2024-03-18 21:22
Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-15 09:52
BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-15 08:25
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(Accesswire)
2024-03-15 08:25
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(Accesswire)
2024-03-15 06:10
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(Accesswire)
2024-03-07 20:00
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024(Accesswire)
2024-02-22 19:40
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules(Accesswire)
2024-02-19 19:10
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG(Accesswire)
2024-02-19 19:05
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules(Accesswire)
2024-02-05 04:15
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use(Accesswire)
2024-02-01 19:07
Why Is Biofrontera (BFRI) Stock Down Today?(Investorplace)
2024-01-11 03:15
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023(Accesswire)
2023-11-21 20:55
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.